Pomerantz LLP is investigating ClearPoint Neuro and some of its executives for potential securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that a Huntington's disease treatment failed to meet key clinical goals in Phase I/II trials. This news caused ClearPoint's shares to fall 23.12% on September 29, 2026. The investigation aims to determine if ClearPoint engaged in unlawful business practices related to this disclosure.
ClearPoint Neuro's shares are trading at USD 8.82 on Pluang as of November 11, 2026, showing a 3.82% decline in the past day. The stock's market capitalization stands at $293.46 million, reflecting its current valuation. Investors typically hold ClearPoint shares for about 12 days on the platform, indicating relatively short-term interest.
